Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Link opens in a new tab
Search content at Icahn School of Medicine at Mount Sinai
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Ferret lung transplant: An orthotopic model of obliterative bronchiolitis
H. Sui
, A. K. Olivier
, J. A. Klesney-Tait
, L. Brooks
, S. R. Tyler
, X. Sun
, A. Skopec
, J. Kline
, P. G. Sanchez
, D. K. Meyerholz
, N. Zavazava
, M. Iannettoni
, J. F. Engelhardt
, K. R. Parekh
Research output
:
Contribution to journal
›
Article
›
peer-review
27
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Ferret lung transplant: An orthotopic model of obliterative bronchiolitis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Ferret
100%
Lung Transplantation
100%
Allograft
100%
Obliterative Bronchiolitis
100%
Orthotopic Model
100%
Acute Rejection
57%
Immunosuppression
42%
Lymphocytic Bronchiolitis
42%
Histologic
28%
Long-term Survivors
28%
Lung Allograft
28%
Fibrosis
14%
Airway
14%
Early Graft Failure
14%
Computed Tomography
14%
Left Temporal Lobe
14%
Late Mortality
14%
Allograft Survival
14%
Occlusion
14%
Transplantation Model
14%
Human Lung
14%
Domestic Ferret
14%
Late Morbidity
14%
Outbred
14%
Immunosuppression Reduction
14%
Allograft Pathology
14%
Bronchiolar
14%
Lung Biology
14%
Immunosuppression Protocol
14%
Chronic Rejection
14%
Histologic Changes
14%
Immunology and Microbiology
Mustela Putorius Furo
100%
Bronchiolitis
100%
Lung Transplantation
100%
Allograft
100%
Immunosuppression
50%
Acute Graft Rejection
40%
Lung
30%
Chronic Graft Rejection
10%
X-Ray Computed Tomography
10%
Morbidity
10%
Airway
10%
Medicine and Dentistry
Allograft
100%
Lung Transplantation
100%
Bronchiolitis Obliterans
100%
Immunosuppressive Treatment
55%
Acute Graft Rejection
44%
Bronchiolitis
33%
Lung
33%
Graft Failure
11%
Fibrosis
11%
Chronic Graft Rejection
11%
Graft Survival
11%
Morbidity
11%
X-Ray Computed Tomography
11%